# A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

> **NCT06234137** · NA · RECRUITING · sponsor: **Wang Ouchen** · enrollment: 154 (estimated)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Inetetamab
- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT06234137
- **Lead sponsor:** Wang Ouchen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-27
- **Primary completion:** 2025-07-31
- **Final completion:** 2031-08-01
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06234137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06234137, "A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06234137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*